Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.51 |
| ▸ | SRC | P12931 | 4/20 | 0.50 |
| ▸ | KIT | P10721 | 2/20 | 0.49 |
| ▸ | FLT3 | P36888 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 2/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SORD | Q00796 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011158 | 1.00 | HRH4 (0.51) | HRH4SRCKITFLT3HRH3 | |
| SCHEMBL11981518 | 0.85 | SORD (0.57) | SRCKITFLT3ABL1KDM4E | |
| SCHEMBL5889036 | 0.84 | CRHBP (0.49) | HRH4HRH3MEN1KMT2A | |
| SCHEMBL31052504 | 0.83 | MAP4K4 (0.50) | HRH4HRH3 | |
| SCHEMBL11929050 | 0.82 | SRC (0.47) | SRCKITFLT3ABL1KDM4E | |
| SCHEMBL2237335 | 0.82 | SRC (0.47) | SRCKITFLT3ABL1KDM4E | |
| SCHEMBL1682840 | 0.82 | SRC (0.47) | SRCKITFLT3HRH3ABL1 | |
| SCHEMBL3286587 | 0.81 | HRH4 (0.72) | HRH4HRH3 | |
| SCHEMBL16809275 | 0.80 | SRC (0.56) | SRCKITFLT3ABL1SIK1 | |
| SCHEMBL21091026 | 0.80 | SRC (0.46) | SRCKITFLT3ABL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3141552-B1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM IND CO LTD (KR) | 2019-04-17 | — | — | EP | claimed |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | HANMI PHARM. CO., LTD. (KR) | 2018-10-30 | — | — | US | claimed |
| EP-3141552-A1 | THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2017-03-15 | — | — | EP | claimed |
| EP-2528920-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | Hanmi Pharm. Co., Ltd. (KR) | 2012-12-05 | — | — | EP | claimed |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-11-29 | — | — | US | claimed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | claimed |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| CN-111269215-B | Nitrogen-containing heterocyclic organic compound and preparation method and application thereof | 中科利健制药(广州)有限公司 | 2021-10-26 | — | — | CN | disclosed |
| EP-3212652-B1 | RIPK2 INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK (CA) | 2021-02-17 | — | — | EP | disclosed |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2020-12-29 | — | — | US | disclosed |
| EP-3035938-B1 | TARGETED THERAPEUTICS | MADRIGAL PHARMACEUTICALS INC (US) | 2020-08-19 | — | — | EP | disclosed |
| CN-111269215-A | Nitrogen-containing heterocyclic organic compound and preparation method and application thereof | 中科利健制药(广州)有限公司 | 2020-06-12 | — | — | CN | disclosed |
| WO-2012035039-A1 | AZABENZOTHIAZOLE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011113802-A2 | IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011093672-A2 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | HANMI PHARM. CO., LTD. (KR) | 2011-08-04 | — | — | WO | disclosed |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2011-06-30 | — | — | US | disclosed |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| US-20090263398-A1 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-22 | — | — | US | disclosed |
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105250-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | ABL1, BCR, PDGFRB | HRH4 4235/4885SRC 11/4885KIT 683/4885 |
| US-20120302567-A1 | BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE | CDK2, SBK3, CDK2AP1 | HRH4 4228/4885SRC 86/4885KIT 1013/4885 |
| US-20100021420-A1 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | CDK9, CDK1, CDK19 | HRH4 228/4885SRC 279/4885KIT 1634/4885 |
| US-20240199626-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | SMN1; SMN2, MCL1, NLN | HRH4 4804/4885SRC 865/4885KIT 3766/4885 |
| US-10875863-B2 | RIPK2 inhibitors and method of treating cancer with same | RIPK2, RIPK1, RIPK4 | HRH4 4518/4885SRC 1394/4885KIT 1206/4885 |
| US-10112954-B2 | Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase | CDK2, SBK3, CDK2AP1 | HRH4 4228/4885SRC 86/4885KIT 1013/4885 |
| US-20090263398-A1 | PHARMACEUTICAL COMBINATIONS | HRH4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP3A4 | HRH4 1/4885SRC 638/4885KIT 2408/4885 |
| US-20110159111-A1 | PHARMACEUTICAL COMBINATIONS | SLC10A1, CYP11B2, SDHB | HRH4 2727/4885SRC 2808/4885KIT 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.